Hazlett, Burt & Watson’s AbbVie ABBV Stock Holding History

Hazlett, Burt & Watson’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.34M	Buy	10,737 +6	+0.1%	+$1.33K	0.73%	30
2025 Q4	$2.45M	Buy	10,731 +387	+4%	+$88.2K	0.78%	27
2025 Q3	$2.39M	Buy	10,344 +756	+8%	+$154K	0.85%	26
2025 Q2	$1.78M	Buy	9,588 +111	+1%	+$20.6K	0.73%	35
2025 Q1	$1.99M	Buy	9,477 +200	+2%	+$38.9K	0.89%	21
2024 Q4	$1.65M	Sell	9,277 -139	-1%	-$25.6K	0.73%	30
2024 Q3	$1.86M	Buy	9,416 +62	+0.7%	+$11.6K	0.85%	23
2024 Q2	$1.6M	Buy	9,354 +4,144	+80%	+$686K	0.83%	27
2024 Q1	$947K	Buy	5,210 +56	+1%	+$9.65K	0.57%	35
2023 Q4	$798K	Hold	5,154	–	–	0.54%	38
2023 Q3	$769K	Buy	5,154 +116	+2%	+$17K	0.57%	31
2023 Q2	$678K	Buy	5,038 +5	+0.1%	+$733	0.51%	31
2023 Q1	$802K	Buy	5,033 +188	+4%	+$28.7K	0.66%	27
2022 Q4	$780K	Sell	4,845 -235	-5%	-$36K	0.69%	27
2022 Q3	$682K	Buy	5,080 +7	+0.1%	+$1K	0.66%	32
2022 Q2	$777K	Buy	5,073 +6	+0.1%	+$917	0.71%	28
2022 Q1	$822K	Buy	+5,067	New	+$736K	0.65%	31

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hazlett, Burt & Watson's ABBV Position: Q1 2026 in Review

Hazlett, Burt & Watson increased its AbbVie (ABBV) stake by 0.06% in Q1 2026, buying an estimated $1.33K and bringing the position to 10,737 shares worth $2.34M. The position accounts for 0.73% of the portfolio, ranked #30.

Hazlett, Burt & Watson first reported a position in ABBV in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.45M in Q4 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Hazlett, Burt & Watson held 10,737 shares of AbbVie worth $2.34M as of Q1 2026.
Hazlett, Burt & Watson bought 6 AbbVie shares in Q1 2026, an estimated $1.33K.
AbbVie made up 0.73% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #30 holding.
Hazlett, Burt & Watson first reported a position in AbbVie in Q1 2022 and has held it in 17 quarters since.
Hazlett, Burt & Watson's AbbVie position peaked at $2.45M in Q4 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.